Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT of 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission File Number 000-30833 BRUKER CORPORATION (Exact name of registrant as specified in its charter) Delaware 04-3110160 (Stat ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

Have you looked into how Bruker (BRKR) performed internationally during the quarter ending December 2025? Considering the widespread global presence of this scientific equipment maker, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inv ...

Core Insights - Bruker Corporation (BRKR) reported adjusted earnings per share (EPS) of 59 cents for Q4 2025, a decline of 22.4% year over year, and missed the Zacks Consensus Estimate by 9.2% [1][7] - The company’s total revenues for Q4 were $977.2 million, a slight decrease of 0.2% year over year, but exceeded the Zacks Consensus Estimate by 1.12% [3][10] - For the full year 2025, adjusted EPS was $1.83, down 24.1% from the previous year [2] Revenue Analysis - Q4 revenues by geography showed a 13.8% decline in the U.S. to $225 million, while Europe saw a 1% increase to $377 million, and Asia Pacific revenues rose 8.3% to $301.2 million [4] - The BSI BioSpin segment revenues fell 2% to $267 million, while BSI CALID revenues increased by 3.4% to $331.6 million [4] - Total revenues for 2025 reached $3.44 billion, reflecting a 2.1% increase from the previous year [3] Margin Performance - Gross profit decreased by 8.9% to $449.2 million, with gross margin contracting by 439 basis points to 46% due to an 8.6% rise in the cost of revenues [5][10] - Adjusted operating profit was $102.4 million, down 27.7% year over year, with adjusted operating margin contracting by 398 basis points to 10.5% [5] Financial Position - At the end of Q4 2025, Bruker had cash and cash equivalents of $298.8 million, an increase from $183.4 million at the end of 2024 [6] - Long-term debt at the end of Q4 2025 was $1.87 billion, down from $2.09 billion at the end of Q4 2024 [8] 2026 Guidance - Bruker provided guidance for 2026, expecting revenues between $3.57 billion and $3.60 billion, indicating a year-over-year growth of 4% to 5% [9] - Adjusted EPS for 2026 is projected to be in the range of $2.10 to $2.15, representing an increase of 15% to 17% year over year [9] Overall Assessment - The company ended Q4 2025 with mixed results, as earnings missed estimates while revenues surpassed them [10] - Margins were negatively impacted by lower volume, unfavorable mix, tariffs, and currency headwinds [10] - Despite challenges, Bruker’s innovation efforts showed promise, with expectations for improved contributions from the BEST segment in 2026 [11]

Bruker Corp (NASDAQ:BRKR) reported mixed fourth-quarter financial results on Thursday.Bruker reported quarterly earnings of 59 cents per share which missed the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $977.200 million which beat the analyst consensus estimate of $960.834 million.Bruker said it sees FY2026 adjusted EPS of $2.10-$2.15, versus market estimates of $2.13. The company sees sales of $3.570 billion-$3.600 billion versus estimates of $3.470 billion.Br ...

Bruker Corp (NASDAQ:BRKR) reported mixed fourth-quarter financial results on Thursday.Bruker reported quarterly earnings of 59 cents per share which missed the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $977.200 million which beat the analyst consensus estimate of $960.834 million.Bruker said it sees FY2026 adjusted EPS of $2.10-$2.15, versus market estimates of $2.13. The company sees sales of $3.570 billion-$3.600 billion versus estimates of $3.470 billion.Br ...

Core Viewpoint - Bruker Corporation is facing challenges in maintaining profit margins despite exceeding revenue estimates, leading to a cautious outlook from analysts [5][6]. Financial Performance - Bruker reported Q4 2025 revenue of $977.2 million, a slight decline of 0.2% year-over-year, but above the Zacks Consensus Estimate of $966.4 million, resulting in a positive surprise of 1.12% [2][6]. - The company's EPS for Q4 2025 was $0.59, which fell short of the consensus estimate of $0.65, representing a negative surprise of 9.23% and a decline from the previous year's EPS of $0.76 [3][6]. Stock Performance - The current stock price of $37.51 reflects an approximate decrease of 11.60% from previous levels, with a market capitalization of about $5.7 billion [4]. - Over the past year, BRKR's stock has fluctuated significantly, reaching a high of $56.22 and a low of $28.53 [4]. Analyst Outlook - Jefferies has lowered the price target for BRKR from $55 to $50, influenced by the recent earnings performance and the decline in EPS, despite the company's ability to exceed revenue estimates [5][6].

Non-GAAP diluted EPS was $0.59, down from $0.76 in the year-ago quarter. On a GAAP basis, diluted EPS was $0.10 versus $0.09. Herman also noted the weighted average diluted share count rose 13% year-over-year to 171.7 million shares, reflecting accounting for the mandatory convertible preferred stock offering completed in September 2025.Non-GAAP operating margin was 15.7%, down 240 basis points year-over-year. CFO Gerald Herman said the margin came in about 100 basis points below the company’s expectations, ...

Bruker (NasdaqGS:BRKR) Q4 2025 Earnings call February 12, 2026 08:30 AM ET Company ParticipantsFrank Laukien - President and CEOGerald Herman - EVP and CFOJoe Kostka - Director of Investor RelationsMichael Ryskin - Managing DirectorTycho Peterson - Managing DirectorConference Call ParticipantsBrandon Couillard - Senior Equity AnalystDan Brennan - Managing Director and Senior Equity Research AnalystDoug Schenkel - Managing Director, Senior Research Analyst, and Head of Life Science & Diagnostic ToolsPuneet S ...

Financial Data and Key Metrics Changes - In Q4 2025, Bruker reported revenues of $977.2 million, approximately flat year-over-year, with a currency tailwind of 4.1% and an organic decline of 5.1% [12][27] - For the full year 2025, reported revenues increased by 2.1% to $3.44 billion, with an organic revenue decline of 3.7% [13][32] - Non-GAAP diluted EPS for Q4 2025 was $0.59, down from $0.76 in Q4 2024, reflecting a 22.4% decrease [30] - Non-GAAP operating margin for Q4 2025 was 15.7%, down 240 basis points year-over-year [29] Business Line Data and Key Metrics Changes - The BioSpin group revenue for 2025 was $879 million, declining in the mid-single digits, with solid growth in Chemspeed lab automation offset by declines in NMR instrumentation [15] - The CALID group had revenue of $1.2 billion with constant exchange rate growth in the high single digits, driven by microbiology and infection diagnostics [17] - Bruker Nano revenues for 2025 were $1.1 billion, declining in the low single digits, with growth in spatial biology offset by declines in academia/government and industrial markets [18] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue declined in the low teens%, while European revenue declined in the high single digits%, and Asia Pacific revenue grew in the high single digits% [28] - The U.S. biopharma and industrial growth looked stronger in the second half of 2025, while U.S. government orders remained weak throughout 2025 [23] Company Strategy and Development Direction - Bruker is focused on expanding its leadership in post-genomic disease research and drug discovery tools, particularly in proteomics and multi-omics [19] - The company aims for significant margin expansion, targeting a 250-300 basis points improvement in operating profit margin for 2026 [11][34] - Bruker plans to leverage its recent acquisitions and product innovations to drive revenue growth in 2026 and beyond [8][24] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the recovery in demand, particularly in biopharma and industrial research, while acknowledging lingering uncertainties in the U.S. government market [9][49] - The company expects to return to organic revenue growth in the second quarter of 2026, driven by improved order momentum and easier year-over-year comparisons [37][60] - Management highlighted the importance of cost-saving initiatives to mitigate headwinds from tariffs and currency fluctuations [42][68] Other Important Information - Bruker ended Q4 2025 with cash, cash equivalents, and short-term investments of approximately $300 million [31] - The company received major multi-year orders worth over $500 million for superconducting wire from large MRI manufacturers, expected to contribute to revenue in 2026 [18] Q&A Session Summary Question: Margin focus and cost initiatives - Management discussed the focus on cost initiatives to improve margins, expecting annualized savings to exceed $140 million [40][42] Question: Academic and government customer interactions - Management noted that while U.S. government orders were weak, there is cautious optimism for improvement in the second half of 2026 [48][49] Question: Revenue pacing and underlying assumptions - Management indicated that both easier year-over-year comparisons and improving order momentum would contribute to revenue growth starting in Q2 2026 [58][60] Question: Expectations for end markets - Management expects low single-digit organic growth in biopharma and semi, with microbiology showing stronger growth due to increased placements of diagnostic platforms [65][67]